BMY
Bristol-Myers Squibb Company
NYSE: BMY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$57.59
-1.15% today
Updated 2026-04-29
Market cap
$119.87B
P/E ratio
16.97
P/S ratio
2.49x
EPS (TTM)
$3.46
Dividend yield
4.22%
52W range
$41 – $62
Volume
11.8M
WallStSmart proprietary scores
62
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B4.5
Quality
C8.5
Profitability
A6.7
Valuation
B6/9
Piotroski F-Score
Moderate
1.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$63.04
+9.46%
12-Month target
$67.13
+16.57%
Intrinsic (DCF)
$87.81
Margin of safety
+31.75%
4 Strong Buy6 Buy18 Hold1 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 40.40% — strong efficiency
+ Free cash flow $1.60B — positive
+ 31.75% below intrinsic value
Risks
- Altman Z 1.42 — distress zone
- Debt/equity 2.55x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $46.16B | $45.01B | $48.30B | $48.19B | $48.19B | $47.6B |
| Net income | $6.33B | $8.03B | $-8.95B | $7.05B | $1.09B | — |
| EPS | — | — | — | — | $3.46 | $6.33 |
| Free cash flow | $11.95B | $12.65B | $13.94B | $12.85B | $1.60B | — |
| Profit margin | 13.71% | 17.83% | -18.53% | 14.63% | 14.60% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | SHANAHAN, KARIN | Sale | 3,307 | — |
| 2026-04-01 | SHANAHAN, KARIN | Buy | 3,307 | — |
| 2026-04-01 | SHANAHAN, KARIN | Sale | 1,692 | $61.73 |
Peer comparison
Smart narrative
Bristol-Myers Squibb Company trades at $57.59. representing a P/E of 16.97x trailing earnings. Our Smart Value Score of 62/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 1.42, it sits in the distress. TTM revenue stands at $48.19B. with profit margins at 14.60%. Our DCF model estimates intrinsic value at $87.81.
Frequently asked questions
What is Bristol-Myers Squibb Company's stock price?
Bristol-Myers Squibb Company (BMY) trades at $57.59.
Is Bristol-Myers Squibb Company overvalued?
Smart Value Score 62/100 (Grade C+, Hold). DCF value $87.81.
What is the price target of Bristol-Myers Squibb Company (BMY)?
The analyst target price is $63.04, representing +9.5% upside from the current price of $57.59.
What is the intrinsic value of Bristol-Myers Squibb Company (BMY)?
Based on our DCF model, intrinsic value is $87.81, a +31.8% margin of safety versus $57.59.
What is the future stock price of BMY by 2030?
Our research-backed model estimates Bristol-Myers Squibb Company could reach $286.08 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Bristol-Myers Squibb Company's revenue?
TTM revenue is $48.19B.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
1.42 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.49x
ROE40.40%
Beta0.27
50D MA$59.70
200D MA$51.72
Shares out2.04B
Float2.03B
Short ratio—
Avg volume11.8M
Performance
1 week-1.91%
1 month-6.71%
3 months+4.61%
YTD+6.77%
1 year—
3 years—
5 years—